Shares of Ventyx Biosciences (VTYX) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi (SNY) . Per the terms of the deal, Sanofi will buy 70,601 of Ventyx’s Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock. The proceeds from this investment are anticipated to enhance Ventyx’s cash reserves. With t ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease. “We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman ...

SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) --  Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company’s SVP of Finance, has assumed the roles of interim Principal Financial Officer an ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: 2024 Wells Fargo Healthcare ConferenceLocation: Boston, MADate: Wednesday, September 4, 2024Time: 11:00-11:35 AM ET Ev ...

临床试验进展 - 公司正在开发一系列针对炎症性疾病的新型小分子产品候选药物[112] - 公司在2024年第一季度报告了VTX3232和VTX2735的正面临床试验结果[112] - 公司计划在2024年下半年启动VTX3232和VTX2735的II期临床试验[112] - 公司在2023年第四季度宣布了VTX002的II期临床试验的阳性结果,正在准备III期临床试验[112] - 公司在2024年第三季度宣布了VTX958的II期临床试验未达到主要终点,不会继续内部开发[112] 财务状况 - 公司2023年和2024年上半年的净亏损分别为1.93亿美元和0.705亿美元[114] - 公司2024年6月30日的累计亏损为4.897亿美元[114] - 公司2023年通过ATM融资方式筹集了5000万美元[118] - 公司2024年3月完成了1亿美元的私募融资[117] - 公司于2022年9月和2024年3月通过私募股票融资分别获得约1.652亿美元和9,500万美元[141] - 公司预计现有现金、现金等价物和有价证券足以满足未来12个月的经营需求[143] - 公司未来资本需求取决于多个因素,包括产品候选物的研发进度和监管审批、制造和商业化费用等[147] - 公司预计未来将通过股权、债务融资或合作等方式筹集资金[148][149] - 经营活动现金流出约7,216万美元[152][153] - 投资活动现金流出约3,376万美元[151] - 筹资活动现金流入约9,528万美元[151] 研发费用 - 研发费用主要用于VTX958、VTX002、VTX2735和VTX3232的临床开发[123] - 研发费用净减少约2,240万美元[137][138] - 一般及行政费用减少约70万美元[139] - 其他收益约为700万美元[140] 会计处理 - 公司管理层讨论和分析基于美国公认会计准则编制的简明合并财务报表,需要做出涉及资产、负债和费用的估计和判断[158] - 2023年12月31日,公司不再是新兴成长公司和小报告公司,不再享受相关的报告豁免[160] - 2024年6月30日,公司重新符合小报告公司的标准,可以享受相关的披露优惠[161]

财务状况 - 公司现金、现金等价物和有价证券为2.797亿美元,预计可为计划的运营提供资金至少到2026年下半年[2] - 公司现金、现金等价物和有价证券总额为27.97亿美元[26] - 公司总资产为30.92亿美元[26] - 公司总负债为2.84亿美元[26] - 公司累计亏损为48.97亿美元[26] - 公司总股东权益为28.08亿美元[26] 研发进展 - 公司预计在2024年下半年启动VTX3232的2期临床试验,用于帕金森病和肥胖及心血管代谢疾病[8,9] - 公司预计在2024年下半年启动VTX2735的2期临床试验,用于复发性心包炎[12] - VTX3232在1期临床试验中展现出良好的药代动力学和药效学特征,有望成为最佳的中枢神经系统渗透型NLRP3抑制剂[7] - VTX2735在2期临床试验中显示对CAPS患者的疾病活性和炎症生物标志物具有临床意义上的改善[11] - VTX002在2期临床试验中展现出良好的疗效和安全性特征,有望成为溃疡性结肠炎的最佳口服药物[13,14] - VTX958在2期克罗恩病临床试验中未达到主要终点,但观察到了剂量依赖性的内镜学反应,公司将进一步分析结果[15] 人事变动 - 公司任命Mark Forman博士为首席医疗官,他将在塑造公司临床策略中发挥关键作用[5,6] 财务表现 - 2024年第二季度研发费用为2780万美元,较2023年同期下降[17] - 2024年第二季度净亏损为3190万美元,较2023年同期下降[19]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (State ...

Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (State or other jurisdiction ...

Exhibit 99.1 Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash equivalents and marketable securities of $252.2 million as of December 31, 2023 are expected to fund operations into at least H2 2025 SAN DIEGO, February 27, 2024 (GLOBE NEWSWIRE) – ...